Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

25.34
+0.86003.51%
Post-market: 25.980.6400+2.53%19:09 EDT
Volume:2.18M
Turnover:54.54M
Market Cap:3.18B
PE:-7.84
High:25.48
Open:24.45
Low:24.13
Close:24.48
52wk High:28.72
52wk Low:7.91
Shares:125.35M
Float Shares:88.65M
Volume Ratio:3.11
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2326
EPS(LYR):-3.2900
ROE:-69.95%
ROA:-23.11%
PB:6.06
PE(LYR):-7.70

Loading ...

Wells Fargo downgrades Arcus Biosciences (RCUS) to a Hold

TIPRANKS
·
Feb 12

Arcus Biosciences Inc. to Host Conference Call on Financial Results and Pipeline Update

Reuters
·
Feb 12

Arcus Biosciences Grants Stock Options and Restricted Stock Units to New Employees

Reuters
·
Jan 27

Arcus’ 2026 Oncology Readouts And Phase 3 Progress Might Change The Case For Investing In RCUS

Simply Wall St.
·
Jan 17

Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs

TIPRANKS
·
Jan 13

Arcus Biosciences Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Jan 08

BRIEF-Arcus Outlines Plans For Casdatifan And Its Inflammation Programs

Reuters
·
Jan 08

Arcus Biosciences Inc - Plans Three Data Readouts for Casdatifan in 2026

THOMSON REUTERS
·
Jan 08

Arcus Biosciences Inc - Expects to Fund Operations Until Second Half of 2028

THOMSON REUTERS
·
Jan 08

Arcus Biosciences President Juan C. Jaen Reports Sale of Common Shares

Reuters
·
Jan 08

Arcus Biosciences CFO Robert C. Goeltz II Reports Disposal of Common Shares

Reuters
·
Jan 03

Have Insiders Sold Arcus Biosciences Shares Recently?

Simply Wall St.
·
Dec 20, 2025

Arcus Biosciences President Juan C. Jaen Reports Sale of Common Shares

Reuters
·
Dec 19, 2025

Arcus Biosciences Inc - First Amendment Extends Maturity Date to Sept 1, 2030, With No Further Extension Right- SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Arcus Biosciences Inc - Amendment Changes Terms for $150 Mln Loan Commitments - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Arcus Biosciences Amends Loan Agreement to Access Up to $150 Million in New Financing

Reuters
·
Dec 19, 2025

Arcus Biosciences CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 19, 2025

Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Benzinga_recent_news
·
Dec 13, 2025

Arcus Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 13, 2025

BUZZ-U.S. STOCKS ON THE MOVE-EastGroup, Boeing, Exxon Mobil

Reuters
·
Dec 13, 2025